Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension (PaRTAkE-PH)
Primary Purpose
Pulmonary Arterial Hypertension
Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Usual Care
Home-based exercise program
Sponsored by
About this trial
This is an interventional supportive care trial for Pulmonary Arterial Hypertension focused on measuring Exercise, Six-minute walk, Heart rate monitor
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of group 1 Pulmonary Atrial Hypertension (PAH) diagnosed during right heart catheterization (RHC) according to WHO criteria 28
- WHO functional class II to III
- Stable clinical condition, with no change in medical therapy for pulmonary arterial hypertension (PAH) for at least 3 months before enrollment
- Planned follow-up at University of Michigan Hospital Centers over at least 1 year
- If enrolled in clinical trial, must be in open-label extension stage on stable medications for at least 3 months.
- Competent to give informed consent
- Have computer and internet access
Exclusion Criteria:
- Life expectancy under 1 year
- Co-morbidities which limit physical activity to a severe degree (i.e., permanently wheelchair bound, musculoskeletal disorders, recent myocardial infarction, unstable arrhythmia)
- Current substance abuse, and/or a severe psychiatric disorder (including severe depression, psychosis, or dementia) which limits the patient's ability to follow the study protocol
- Recently completed (<6 months), current enrollment or planned enrollment in pulmonary rehab.
- ≥30 minutes of exercise, ≥ 1 day per week for the previous 3 months
- Six-minute walk distance <150 meters or >550 meters
- Moderate or severe obstructive lung disease forced expiratory volume/forced vital capacity (FEV1/FVC) < 70% and FEV1 < 65% of predicted value after bronchodilator administration).
- Moderate or severe restrictive lung disease (total lung capacity < 60% predicted value).
- Arterial oxygen saturation (SpO2) <88% during 6-minute walk test on baseline home oxygen prescription if applicable or SpO2 <80% if uncorrected shunt.
- History of exercise-induced syncope or arrhythmias.
- Pregnancy or lactation
- Non-English speaking
Sites / Locations
- The University of Michigan
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Usual Care
Home-based exercise program
Arm Description
Usual care administered at the Pulmonary Arterial Hypertension (PAH) clinic at the University of Michigan.
Home-based individualized exercise program based on heart rate reserve (HRR).
Outcomes
Primary Outcome Measures
Efficacy of a home-based exercise training as measured by change in six-minute walk distance
Distance measured in meters
Secondary Outcome Measures
Efficacy of a home-based exercise training as measured by change in six-minute walk distance
Distance measured in meters
Change in physical activity as measured by daily activity captured using the pedometer step count
average daily step counts measured by a pedometer
Change in physical activity as measured by daily activity captured using the pedometer step count
average daily step counts measured by a pedometer
Efficacy of a home-based exercise training as measured by change in treadmill exercise time
Efficacy of a home-based exercise training as measured by change in survey score from the EuroQol five dimension, five level (EQ-5D-5L) questionnaire.
Health related quality of life assessed using the EuroQol EQ-5D-5L. There is a descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The survey visual analog scale (VAS) records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
The users guide gives details of the scoring system: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf
Efficacy of a home-based exercise training as measured by change in survey score from the EuroQol five dimension, five level (EQ-5D-5L) questionnaire.
Health related quality of life assessed using the EuroQol EQ-5D-5L. There is a descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The survey visual analog scale (VAS) records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
The users guide gives details of the scoring system: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf
Efficacy of a home-based exercise training as measured by change in survey score The Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)
PAH-SYMPACT (Pulmonary Arterial Hypertension-Symptoms and Impact) is a self-rating questionnaire to assess symptoms and their physical and cognitive/emotional impact. The PAH-SYMPACT™ questionnaire consists of four domains: Cardiopulmonary Symptoms Domain (scored 0-24), Cardiovascular Symptoms Domain (scored 0-20), Physical Impacts Domain (scored 0-28), and the Cognitive/Emotional Impacts Domain (scored 0-16). In each domain a higher score indicates worse symptoms.
Efficacy of a home-based exercise training as measured by change in survey score The Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)
PAH-SYMPACT (Pulmonary Arterial Hypertension-Symptoms and Impact) is a self-rating questionnaire to assess symptoms and their physical and cognitive/emotional impact. The PAH-SYMPACT™ questionnaire consists of four domains: Cardiopulmonary Symptoms Domain (scored 0-24), Cardiovascular Symptoms Domain (scored 0-20), Physical Impacts Domain (scored 0-28), and the Cognitive/Emotional Impacts Domain (scored 0-16). In each domain a higher score indicates worse symptoms.
Efficacy of a home-based exercise training as measured by change in survey score International Physical Activity Questionnaire Short Form (IPAQ-SF)
The IPAQ-SF is 4 generic item questionnaire (7 questions). About physical activity time in the past 7 days.
Efficacy of a home-based exercise training as measured by change in survey score International Physical Activity Questionnaire Short Form (IPAQ-SF)
The IPAQ-SF is 4 generic item questionnaire (7 questions). About physical activity time in the past 7 days.
Efficacy of a home-based exercise training as measured by change in survey score Patient Health Questionnaire (PHQ)-8
The PHQ-8 questionnaire about depression and is 8 items long. Each question ranges from 0 (not at all) to 3 (nearly every day) for a total possible score of 24 where higher score means more burdensome.
Efficacy of a home-based exercise training as measured by change in survey score Patient Health Questionnaire (PHQ)-8
The PHQ-8 questionnaire about depression and is 8 items long. Each question ranges from 0 (not at all) to 3 (nearly every day) for a total possible score of 24 where higher score means more burdensome.
Efficacy of a home-based exercise training as measured by change in World Health Organization (WHO) functional class
The World Health Organization (WHO) functional class system was created to define the severity of an individual's symptoms and how they impact on day-to-day activities. The functional classes range from I to IV with IV having worse daily impairments.
Efficacy of a home-based exercise training as measured by change in World Health Organization (WHO) functional class
The World Health Organization (WHO) functional class system was created to define the severity of an individual's symptoms and how they impact on day-to-day activities. The functional classes range from I to IV with IV having worse daily impairments.
Full Information
NCT ID
NCT04254289
First Posted
February 2, 2020
Last Updated
September 28, 2023
Sponsor
University of Michigan
Collaborators
Actelion
1. Study Identification
Unique Protocol Identification Number
NCT04254289
Brief Title
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
Acronym
PaRTAkE-PH
Official Title
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 2023 (Anticipated)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
September 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan
Collaborators
Actelion
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The researchers are investigating if changing an individual's behaviors may have an impact on outcomes for patients with pulmonary arterial hypertension (PAH). This research will test the efficacy of a home-based exercise program to improve exercise tolerance and physical activity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Arterial Hypertension
Keywords
Exercise, Six-minute walk, Heart rate monitor
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Masking Description
An independent statistician will develop the randomization schedule and an unblinded study team member will document and maintain the treatment assignment log. The investigators will be adjusting the exercise regimens of those randomized to the exercise program and are unable to be blinded. All patients will receive weekly telephone calls to review activity logs. Outcomes included in the primary and secondary analysis will be blinded as possible. The staff performing the 6-minute walk test (6MWT) and interpreting echocardiograms will be blinded to the group assignment.
Allocation
Randomized
Enrollment
54 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Usual Care
Arm Type
Active Comparator
Arm Description
Usual care administered at the Pulmonary Arterial Hypertension (PAH) clinic at the University of Michigan.
Arm Title
Home-based exercise program
Arm Type
Experimental
Arm Description
Home-based individualized exercise program based on heart rate reserve (HRR).
Intervention Type
Behavioral
Intervention Name(s)
Usual Care
Intervention Description
Usual care
Intervention Type
Behavioral
Intervention Name(s)
Home-based exercise program
Intervention Description
Home-based program determined by exercise physiologist
Primary Outcome Measure Information:
Title
Efficacy of a home-based exercise training as measured by change in six-minute walk distance
Description
Distance measured in meters
Time Frame
Baseline, 12 weeks
Secondary Outcome Measure Information:
Title
Efficacy of a home-based exercise training as measured by change in six-minute walk distance
Description
Distance measured in meters
Time Frame
Baseline, 6 months
Title
Change in physical activity as measured by daily activity captured using the pedometer step count
Description
average daily step counts measured by a pedometer
Time Frame
Baseline, 12 weeks
Title
Change in physical activity as measured by daily activity captured using the pedometer step count
Description
average daily step counts measured by a pedometer
Time Frame
Baseline, 6 months
Title
Efficacy of a home-based exercise training as measured by change in treadmill exercise time
Time Frame
Baseline, 12 weeks
Title
Efficacy of a home-based exercise training as measured by change in survey score from the EuroQol five dimension, five level (EQ-5D-5L) questionnaire.
Description
Health related quality of life assessed using the EuroQol EQ-5D-5L. There is a descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The survey visual analog scale (VAS) records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
The users guide gives details of the scoring system: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf
Time Frame
Baseline, 12 weeks
Title
Efficacy of a home-based exercise training as measured by change in survey score from the EuroQol five dimension, five level (EQ-5D-5L) questionnaire.
Description
Health related quality of life assessed using the EuroQol EQ-5D-5L. There is a descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The survey visual analog scale (VAS) records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
The users guide gives details of the scoring system: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf
Time Frame
Baseline, 6 months
Title
Efficacy of a home-based exercise training as measured by change in survey score The Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)
Description
PAH-SYMPACT (Pulmonary Arterial Hypertension-Symptoms and Impact) is a self-rating questionnaire to assess symptoms and their physical and cognitive/emotional impact. The PAH-SYMPACT™ questionnaire consists of four domains: Cardiopulmonary Symptoms Domain (scored 0-24), Cardiovascular Symptoms Domain (scored 0-20), Physical Impacts Domain (scored 0-28), and the Cognitive/Emotional Impacts Domain (scored 0-16). In each domain a higher score indicates worse symptoms.
Time Frame
Baseline, 12 weeks
Title
Efficacy of a home-based exercise training as measured by change in survey score The Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)
Description
PAH-SYMPACT (Pulmonary Arterial Hypertension-Symptoms and Impact) is a self-rating questionnaire to assess symptoms and their physical and cognitive/emotional impact. The PAH-SYMPACT™ questionnaire consists of four domains: Cardiopulmonary Symptoms Domain (scored 0-24), Cardiovascular Symptoms Domain (scored 0-20), Physical Impacts Domain (scored 0-28), and the Cognitive/Emotional Impacts Domain (scored 0-16). In each domain a higher score indicates worse symptoms.
Time Frame
Baseline, 6 months
Title
Efficacy of a home-based exercise training as measured by change in survey score International Physical Activity Questionnaire Short Form (IPAQ-SF)
Description
The IPAQ-SF is 4 generic item questionnaire (7 questions). About physical activity time in the past 7 days.
Time Frame
Baseline, 12 weeks
Title
Efficacy of a home-based exercise training as measured by change in survey score International Physical Activity Questionnaire Short Form (IPAQ-SF)
Description
The IPAQ-SF is 4 generic item questionnaire (7 questions). About physical activity time in the past 7 days.
Time Frame
Baseline, 6 months
Title
Efficacy of a home-based exercise training as measured by change in survey score Patient Health Questionnaire (PHQ)-8
Description
The PHQ-8 questionnaire about depression and is 8 items long. Each question ranges from 0 (not at all) to 3 (nearly every day) for a total possible score of 24 where higher score means more burdensome.
Time Frame
Baseline, 12 weeks
Title
Efficacy of a home-based exercise training as measured by change in survey score Patient Health Questionnaire (PHQ)-8
Description
The PHQ-8 questionnaire about depression and is 8 items long. Each question ranges from 0 (not at all) to 3 (nearly every day) for a total possible score of 24 where higher score means more burdensome.
Time Frame
Baseline, 6 months
Title
Efficacy of a home-based exercise training as measured by change in World Health Organization (WHO) functional class
Description
The World Health Organization (WHO) functional class system was created to define the severity of an individual's symptoms and how they impact on day-to-day activities. The functional classes range from I to IV with IV having worse daily impairments.
Time Frame
Baseline, 12 weeks
Title
Efficacy of a home-based exercise training as measured by change in World Health Organization (WHO) functional class
Description
The World Health Organization (WHO) functional class system was created to define the severity of an individual's symptoms and how they impact on day-to-day activities. The functional classes range from I to IV with IV having worse daily impairments.
Time Frame
Baseline, 6 months
Other Pre-specified Outcome Measures:
Title
Change in heart rate recovery
Time Frame
Baseline, 12 weeks
Title
Change in echocardiographic assessment of right ventricle size
Time Frame
Baseline, 12 weeks
Title
Change in echocardiographic assessment of right ventricle function
Time Frame
Baseline, 12 weeks
Title
Percent change in brain natriuretic peptide
Time Frame
Baseline, 12 weeks
Title
Change in number of low risk criteria
Description
Criteria include: World Health Organization (WHO) functional class I/II, six-minute walk distance >440 m, brain natriuretic peptide (BNP) <50)
Time Frame
Baseline, 12 weeks
Title
Frequency of completion of activity logs
Time Frame
Up to 12 weeks
Title
Frequency of completion of weekly telephone follow-ups
Time Frame
Up to 12 weeks
Title
Number of low risk criteria
Description
Criteria include: World Health Organization (WHO) functional class I/II, six-minute walk distance >440 m, brain natriuretic peptide (BNP) <50
Time Frame
6 months
Title
Number of hospitalizations for pulmonary hypertension
Time Frame
12 weeks
Title
Number of hospitalizations for pulmonary hypertension
Time Frame
6 months
Title
Frequency of Death
Time Frame
Up to 12 weeks
Title
Frequency of Death
Time Frame
Up to 6 months
Title
Frequency worsening WHO functional class
Description
WHO functional class higher than previously noted. The World Health Organization (WHO) functional class system was created to define the severity of an individual's symptoms and how they impact on day-to-day activities. The functional classes range from I to IV with IV having worse daily impairments.
Time Frame
12 weeks
Title
Frequency worsening World Health Organization (WHO) functional class
Description
WHO functional class higher than previously noted. The WHO functional class system was created to define the severity of an individual's symptoms and how they impact on day-to-day activities. The functional classes range from I to IV with IV having worse daily impairments.
Time Frame
6 months
Title
Frequency of need for escalation of pulmonary hypertension therapy
Description
Escalation implies dose increase is define as increase of existing therapy or addition of new medication for pulmonary arterial hypertension.
Time Frame
Up to 12 weeks
Title
Frequency of need for escalation of pulmonary hypertension therapy
Description
Escalation implies dose increase is define as increase of existing therapy or addition of new medication for pulmonary arterial hypertension.
Time Frame
Up to 6 months
Title
Frequency of syncope
Time Frame
12 weeks
Title
Frequency of syncope
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of group 1 Pulmonary Atrial Hypertension (PAH) diagnosed during right heart catheterization (RHC) according to WHO criteria 28
WHO functional class II to III
Stable clinical condition, with no change in medical therapy for pulmonary arterial hypertension (PAH) for at least 3 months before enrollment
Planned follow-up at University of Michigan Hospital Centers over at least 1 year
If enrolled in clinical trial, must be in open-label extension stage on stable medications for at least 3 months.
Competent to give informed consent
Have computer and internet access
Exclusion Criteria:
Life expectancy under 1 year
Co-morbidities which limit physical activity to a severe degree (i.e., permanently wheelchair bound, musculoskeletal disorders, recent myocardial infarction, unstable arrhythmia)
Current substance abuse, and/or a severe psychiatric disorder (including severe depression, psychosis, or dementia) which limits the patient's ability to follow the study protocol
Recently completed (<6 months), current enrollment or planned enrollment in pulmonary rehab.
≥30 minutes of exercise, ≥ 1 day per week for the previous 3 months
Six-minute walk distance <150 meters or >550 meters
Moderate or severe obstructive lung disease forced expiratory volume/forced vital capacity (FEV1/FVC) < 70% and FEV1 < 65% of predicted value after bronchodilator administration).
Moderate or severe restrictive lung disease (total lung capacity < 60% predicted value).
Arterial oxygen saturation (SpO2) <88% during 6-minute walk test on baseline home oxygen prescription if applicable or SpO2 <80% if uncorrected shunt.
History of exercise-induced syncope or arrhythmias.
Pregnancy or lactation
Non-English speaking
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Cascino, MD
Phone
734-232-0112
Email
tcascino@umich.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Cascino, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Cascino
Phone
734-232-0112
Email
tcascino@umich.edu
First Name & Middle Initial & Last Name & Degree
Vallerie McLaughlin
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension
We'll reach out to this number within 24 hrs